Cargando…

Association of delayed chemoradiotherapy with elevated Epstein-Barr virus DNA load and adverse clinical outcome in nasopharyngeal carcinoma treatment during the COVID-19 pandemic: a retrospective study

BACKGROUND: To summarize the impact of radiotherapy (RT) and chemotherapy delays on patients with nasopharyngeal carcinoma (NPC) during the COVID-19 pandemic. METHODS: We retrospectively included 233 patients with stage II-IVa NPC treated with RT and chemotherapy between December 11, 2019 and March...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Cheng-Long, Fang, Xue-Liang, Mao, Yan-Ping, Guo, Rui, Li, Wen-Fei, Xu, Si-Si, Ma, Jun, Chen, Lei, Tang, Ling-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623943/ https://www.ncbi.nlm.nih.gov/pubmed/36316696 http://dx.doi.org/10.1186/s12935-022-02748-y

Ejemplares similares

Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2016)

Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening
por: Chen, Yufeng, et al.
Publicado: (2015)

Nasopharyngeal Epstein‐Barr virus DNA loads in high‐risk nasopharyngeal carcinoma families: Familial aggregation and host heritability
por: Zheng, Mei‐Qi, et al.
Publicado: (2020)

Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status
por: Peng, Hao, et al.
Publicado: (2016)

Epstein-Barr virus and nasopharyngeal carcinoma
por: Young, Lawrence S., et al.
Publicado: (2014)

The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA
por: Jin, Ya-Nan, et al.
Publicado: (2017)

Role of Epstein-Barr Virus in the Development of Nasopharyngeal Carcinoma
por: Zhang, Hui, et al.
Publicado: (2017)

Roles of Inflammasomes in Epstein–Barr Virus-Associated Nasopharyngeal Cancer
por: Looi, Chin King, et al.
Publicado: (2021)

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
por: Yao, Ji‐Jin, et al.
Publicado: (2017)

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
por: Hau, Pok Man, et al.
Publicado: (2020)

The role of Epstein–Barr virus in nasopharyngeal carcinoma
por: Su, Zhi Yi, et al.
Publicado: (2023)

Quantification of Epstein–Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China
por: Zheng, Xiao-Hui, et al.
Publicado: (2015)

Prognostic Value of Oral Epstein–Barr Virus DNA Load in Locoregionally Advanced Nasopharyngeal Carcinoma
por: He, Yong-Qiao, et al.
Publicado: (2022)

Relationship between pretreatment concentration of plasma Epstein‐Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation
por: Peng, Liang, et al.
Publicado: (2018)

Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells
por: Tsang, Chi Man, et al.
Publicado: (2014)

Natural Variations in BRLF1 Promoter Contribute to the Elevated Reactivation Level of Epstein-Barr Virus in Endemic Areas of Nasopharyngeal Carcinoma
por: Zhang, Jiang-Bo, et al.
Publicado: (2018)

Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma
por: Ji, M F, et al.
Publicado: (2007)

Clinical outcomes of residual or recurrent nasopharyngeal carcinoma treated with endoscopic nasopharyngectomy plus chemoradiotherapy or with chemoradiotherapy alone: a retrospective study
por: Weng, Jingjin, et al.
Publicado: (2017)

The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma
por: Li, You Quan, et al.
Publicado: (2018)

Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis
por: Alami, Imane EL, et al.
Publicado: (2022)

Positivity of both plasma Epstein–Barr virus DNA and serum Epstein–Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma
por: Zhao, Fei-Peng, et al.
Publicado: (2014)

Expression of Interleukin-8, Interleukin-10 and Epstein-Barr Viral-Load as Prognostic Indicator in Nasopharyngeal Carcinoma
por: Savitri, Eka, et al.
Publicado: (2015)

Epstein-Barr virus-encoded LMP1 regulated Pim1 kinase expression promotes nasopharyngeal carcinoma cells proliferation
por: Ding, Ran-ran, et al.
Publicado: (2019)

Epstein-Barr Virus Mediated Signaling in Nasopharyngeal Carcinoma Carcinogenesis
por: Richardo, Timmy, et al.
Publicado: (2020)

Nasopharyngeal Carcinoma: The Role of the EGFR in Epstein–Barr Virus Infection
por: Peng, Xintong, et al.
Publicado: (2021)

Radiotherapy Alone Versus Concurrent or Adjuvant Chemoradiotherapy for Nasopharyngeal Carcinoma Patients with Negative Epstein–Barr Virus DNA after Induction Chemotherapy
por: Kong, Fangfang, et al.
Publicado: (2023)

Clonal dynamics of tumor-infiltrating T-cell receptor beta-chain repertoires in the peripheral blood in response to concurrent chemoradiotherapy for Epstein–Barr virus-associated nasopharyngeal carcinoma
por: Chung, Yih-Lin, et al.
Publicado: (2021)

Elevated plasma fibrinogen level shows superior prognostic value than Epstein–Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era
por: Lan, Mei, et al.
Publicado: (2016)

Epstein-Barr virus DNA loads in the peripheral blood cells predict the survival of locoregionally-advanced nasopharyngeal carcinoma patients
por: He, Yongqiao, et al.
Publicado: (2021)

Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study
por: Guo, Shan-Shan, et al.
Publicado: (2016)

Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study
por: Lv, Jia-Wei, et al.
Publicado: (2016)

Patients with systemic lupus erythematosus have abnormally elevated Epstein–Barr virus load in blood
por: Moon, Uk Yeol, et al.
Publicado: (2004)

Dynamic changes in plasma Epstein–Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study
por: He, Sha‐Sha, et al.
Publicado: (2018)

Epstein-Barr virus in nasopharyngeal and salivary gland carcinomas of Greenland Eskimoes.
por: Saemundsen, A. K., et al.
Publicado: (1982)

Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma
por: Hutajulu, Susanna Hilda, et al.
Publicado: (2014)

The Criteria to Confirm the Role of Epstein-Barr Virus in Nasopharyngeal Carcinoma Initiation
por: Gu, Ai-Di, et al.
Publicado: (2012)

Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma
por: Chan, K.C. Allen
Publicado: (2014)

Identification of genes involved in Epstein-Barr virus-associated nasopharyngeal carcinoma
por: Wang, Junguo, et al.
Publicado: (2016)

Correlation of nasopharyngeal carcinoma with rare earth elements and the Epstein-Barr virus
por: Zhang, Xiangmin, et al.
Publicado: (2018)

Rearranged Epstein‐Barr Virus Genomes and Clonal Origin in Nasopharyngeal Carcinoma
por: Shimakage, Misuzu, et al.
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_pu1vg049t00djnond5rk797k2s